ReviewSynthetic and systems biotechnology2026
Eukaryotic cell-free protein synthesis: Chassis diversification, system engineering, and emerging applications.
Review in Synthetic and systems biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eukaryotic cell-free protein synthesis (CFPS) system, endowed with intrinsic post-translational modification capabilities and a complex molecular chaperone network, efficiently synthesizes functional proteins with correct conformation and biological activity. This effectively compensates for the structural limitations of prokaryotic systems in expressing complex eukaryotic proteins. This paper aims to comprehensively review and analyze the latest advances in the field of eukaryotic CFPS from a systems engineering perspective. The paper delves into the diversification of host chassis, rational design of core reaction components, and the pivotal role of novel biomaterial integration and high-throughput reaction equipment development in system reconfiguration. At the application level, it summarizes the platform's latest achievements, including elucidation of fundamental mechanisms, complex protein engineering, and metabolic synthesis. It particularly highlights its potential in emerging areas such as the construction of artificial cells, the development of bioelectronic interfaces, and the design of microarray chips. Furthermore, addressing the current standardization and cost bottlenecks hindering industrialization, this paper proposes a solution strategy based on artificial intelligence and synthetic biology tools, aligning with the shift from empirical trial-and-error to rational design paradigms. By integrating the current technological landscape with emerging trends, this review aims to provide theoretical references and practical guidance for constructing an economical, high-throughput eukaryotic cell-free biomanufacturing platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.